MiR-218-5p Restores Sensitivity to Gemcitabine Through PRKCE/MDR1 Axis in Gallbladder Cancer

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2017 May 12

PMID 28492560

Citations 37

Authors

Hui Wang

Ming Zhan

Sun-Wang Xu

Wei Chen

Man-Mei Long

Yong-Heng Shi

Qiang Liu

Man Mohan

Jian Wang

Affiliations

Soon will be listed here.

Abstract

Gallbladder cancer (GBC) is one of the most common malignancy of the biliary tract characterized by its high chemoresistant tendency. Although great progresses have been made in recent decades for treating many cancers with anticancer drugs, effective therapeutics methods for anti-GBC are still lacking. Therefore, investigations into identifying the mechanisms underlying the drug resistance of GBC are greatly needed. In this study, we show that miR-218-5p plays a critical role in gemcitabine resistance of GBC. miR-218-5p levels were significantly lower in GBC than adjacent non-cancer tissues, and which were also associated with patient prognosis. While miR-218-5p overexpression abrogated gemcitabine resistance of GBC cells, silencing of which exhibited the opposite effects. Via six microRNA targets prediction algorithms, we found that PRKCE is a potential target of miR-218-5p. Moreover, miR-218-5p overexpression repressed the luciferase activity of reporter constructs containing 3'-UTR of PRKCE and also reduced PRKCE expression. Further studies revealed that miR-218-5p promotes sensitivity of gemcitabine by abolishing PRKCE-induced upregulation of MDR1/P-gp. Taken together, our results imply that an intimate correlation between miR-218-5p and PRKCE/MDR1 axis abnormal expression is a key determinant of gemcitabine tolerance, and suggest a novel miR-218-5p-based clinical intervention target for GBC patients.

Citing Articles

MiRNAs: main players of cancer drug resistance target ABC transporters.

Mohammadi F, Nejatollahi M, Sheikhnia F, Ebrahimi Y, Mohammadi M, Rashidi V Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39808313 DOI: 10.1007/s00210-024-03719-y.

Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer.

Gu Y, Yang R, Zhang Y, Guo M, Takehiro K, Zhan M Mol Biomed. 2025; 6(1):2.

PMID: 39757310 PMC: 11700966. DOI: 10.1186/s43556-024-00239-2.

MicroRNA‑223 overexpression suppresses protein kinase C ε expression in human leukemia stem cell‑like KG‑1a cells.

Osiriphan M, Insukhin C, Anuchapreeda S, Khamphikham P, Duangmano S Mol Clin Oncol. 2024; 21(1):48.

PMID: 38881704 PMC: 11176719. DOI: 10.3892/mco.2024.2746.

Impact of ABCB1 and ABCG2 Transporter in Outcome of Gallbladder Cancer.

Nimisha , Saluja S, Sharma A, Nekarakanti P, Apurva , Kumar A J Clin Exp Hepatol. 2024; 14(5):101410.

PMID: 38716375 PMC: 11070335. DOI: 10.1016/j.jceh.2024.101410.

Micro-RNAs With Prognostic Significance in Gallbladder Cancer: A Systematic Review and Meta-Analysis.

Saxena R, Krishnan M P S, Christudass C, Chauhan A, Malik V, Gupta A Cureus. 2024; 16(3):e55515.

PMID: 38576631 PMC: 10990876. DOI: 10.7759/cureus.55515.

References

Krech T, Scheuerer E, Geffers R, Kreipe H, Lehmann U, Christgen M . ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells. Cancer Lett. 2011; 315(2):153-60. DOI: 10.1016/j.canlet.2011.09.038. View

He L, Hannon G . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31. DOI: 10.1038/nrg1379. View

Chan B, Manley J, Lee J, Singh S . The emerging roles of microRNAs in cancer metabolism. Cancer Lett. 2014; 356(2 Pt A):301–8. DOI: 10.1016/j.canlet.2014.10.011. View

Huang B, Fu S, Fan W, Wang Z, Chen Z, Guo S . PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P. Cancer Lett. 2016; 376(1):148-54. DOI: 10.1016/j.canlet.2016.03.041. View

Ma M, Chu B, Zhang Y, Weng M, Qin Y, Gong W . Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis. 2015; 6:e1583. PMC: 4669740. DOI: 10.1038/cddis.2014.541. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Martinez I, Gardiner A, Board K, Monzon F, Edwards R, Khan S . Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 2007; 27(18):2575-82. PMC: 2447163. DOI: 10.1038/sj.onc.1210919. View

Liu Y, Cai Q, Bao P, Su Y, Cai H, Wu J . Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes. Breast Cancer Res Treat. 2015; 152(1):183-191. PMC: 4484742. DOI: 10.1007/s10549-015-3460-x. View

Xuan Y, Yang H, Zhao L, Lau W, Lau B, Ren N . MicroRNAs in colorectal cancer: small molecules with big functions. Cancer Lett. 2014; 360(2):89-105. DOI: 10.1016/j.canlet.2014.11.051. View

10.

Wu Q, Yang Z, Nie Y, Shi Y, Fan D . Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014; 347(2):159-66. DOI: 10.1016/j.canlet.2014.03.013. View

11.

Zhan M, Zhao X, Wang H, Chen W, Xu S, Wang W . miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. Tumour Biol. 2016; 37(8):10553-62. DOI: 10.1007/s13277-016-4957-6. View

12.

Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E . The role of site accessibility in microRNA target recognition. Nat Genet. 2007; 39(10):1278-84. DOI: 10.1038/ng2135. View

13.

Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C . Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2015; 370(1):153-64. DOI: 10.1016/j.canlet.2015.10.010. View

14.

Betel D, Koppal A, Agius P, Sander C, Leslie C . Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 2010; 11(8):R90. PMC: 2945792. DOI: 10.1186/gb-2010-11-8-r90. View

15.

de Groen P, Gores G, Larusso N, Gunderson L, Nagorney D . Biliary tract cancers. N Engl J Med. 1999; 341(18):1368-78. DOI: 10.1056/NEJM199910283411807. View

16.

Li X, Dong Y, Wang W, Wang H, Chen Y, Shi G . Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma. Stem Cells Dev. 2012; 22(4):554-66. PMC: 3564469. DOI: 10.1089/scd.2011.0709. View

17.

Lazcano-Ponce E, Miquel J, Munoz N, Herrero R, Ferrecio C, Wistuba I . Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2002; 51(6):349-64. DOI: 10.3322/canjclin.51.6.349. View

18.

Wu D, Cheng Y, Wang J, Chen C, Lee H . Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res. 2010; 70(24):10392-401. DOI: 10.1158/0008-5472.CAN-10-2341. View

19.

Chiu K, Kuo T, Kuok Q, Lin Y, Hua C, Lin C . ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis. Sci Rep. 2015; 5:16426. PMC: 4639752. DOI: 10.1038/srep16426. View

20.

Lee S, La Lee Y, Lee Y, Park S, Kim I, Choi T . Enhanced antitumor effects by combination gene therapy using MDR1 gene shRNA and HSV1-tk in a xenograft mouse model. Cancer Lett. 2009; 291(1):83-9. DOI: 10.1016/j.canlet.2009.10.002. View